Rapid resolution of symptoms with ciprofloxacin therapy in 3859 hospitalised patients with urinary tract infection.
This post-marketing surveillance study including 3859 hospitalised patients with urinary tract infection (UTI) was conducted to evaluate the efficacy and tolerability of treatment with intravenous or orally administered ciprofloxacin. The most frequent initial doses of ciprofloxacin were a total daily dose of 400 mg intravenously and 500 mg orally. After 4 days of therapy, 75.6% of patients were asymptomatic and, 92.0% after 7 days. 93.9% of patients were rated as having improved or have been cured at the end of the observation period. Improvement and cure were independent of the severity of infection. The tolerability of the treatment was rated by physicians as good or very good for 96.9% of patients. Adverse events were reported in 3.5% of patients.
Naber
K G
KG
Urologic Clinic, Hospital St Elisabeth, Straubing, Germany.
Landen
H
H
D000890:Anti-Infective Agents / Q000009:adverse effects / Q000627:therapeutic use; D015992:Body Mass Index; D002939:Ciprofloxacin / Q000009:adverse effects / Q000627:therapeutic use*; D006801:Humans; D007297:Inpatients; D008875:Middle Aged; D015203:Reproducibility of Results; D012449:Safety; D016896:Treatment Outcome; D014552:Urinary Tract Infections / Q000188:drug therapy*
D000890:Anti-Infective Agents; D002939:Ciprofloxacin